Gene Editing of the Endogenous Cryptic 3′ Splice Site Corrects the RNA Splicing Defect in the β 654 -Thalassemia Mouse Model
Human Gene Therapy · 2024
DOI: 10.1089/hum.2023.202 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, 2024. Verfasst von Dan Lu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Medical Genetics, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Gene Editing, beta-Thalassemia, Disease Models, Animal, RNA Splice Sites. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
β 654 -thalassemia is caused by a point mutation in the second intron (IVS-II) of the β-globin gene that activates a cryptic 3′ splice site, leading to incorrect RNA splicing. Our previous study demonstrated that when direct deletion of the β 654 mutation sequence or the cryptic 3′ splice site in the IVS-II occurs, correct splicing of β-globin mRNA can be restored. Herein, we conducted an in-depth analysis to explore a more precise gene-editing method for treating β 654 -thalassemia. A single-base substitution of the cryptic 3′ acceptor splice site was introduced in the genome of a β 654 -thalassemia mouse model using clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9(Cas9)-mediated homology-directed repair (HDR). All of the HDR-edited mice allow the detection of correctly spliced β-globin mRNA. Pathological changes were improved compared with the nonedited β 654 mice. This resulted in a more than twofold increase in the survival rate beyond the weaning age of the mice carrying the β 654 allele. The therapeutic effects of this gene-editing strategy showed that the typical β-thalassemia phenotype can be improved in a dose-dependent manner when the frequency of HDR is over 20%. Our research provides a unique and effective method for correcting the splicing defect by gene editing the reactive splicing acceptor site in a β 654 mouse model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Medical Genetics, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Histo-Embryology, Genetics and Developmental Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- NHC Key Laboratory of Medical Embryogenesis and Developmental Molecular Biology & Shanghai Key Laboratory of Embryo and Reproduction Engineering, Shanghai, China.
- Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai,…
- School of Pharmacy, Macau University of Science and Technology, Macau, China.
ORCID-Profile: Dan Lu, Fanyi Zeng
Zitieren
APA
Lu, D., Gong, X., Guo, X., Cai, Q., Chen, Y., Zhu, Y., Sang, X., Yang, H., Xu, M., Zeng, Y., Li, D., & Zeng, F. (2024). Gene Editing of the Endogenous Cryptic 3′ Splice Site Corrects the RNA Splicing Defect in the β 654 -Thalassemia Mouse Model. Human Gene Therapy. https://doi.org/10.1089/hum.2023.202
Vancouver
Lu D, Gong X, Guo X, Cai Q, Chen Y, Zhu Y, et al. Gene Editing of the Endogenous Cryptic 3′ Splice Site Corrects the RNA Splicing Defect in the β 654 -Thalassemia Mouse Model. Human Gene Therapy. 2024. doi:10.1089/hum.2023.202
BibTeX
@article{Lu2024,
author = {Lu, Dan and Gong, Xiuli and Guo, Xinbing and Cai, Qin and Chen, Yanwen and Zhu, Yiwen and Sang, Xiao and Yang, Hua and Xu, Miao and Zeng, Yitao and Li, Dali and Zeng, Fanyi},
title = {Gene Editing of the Endogenous Cryptic 3′ Splice Site Corrects the RNA Splicing Defect in the β 654 -Thalassemia Mouse Model},
journal = {Human Gene Therapy},
year = {2024},
doi = {10.1089/hum.2023.202}
}
EUVIMED